1-7 of 7
Lini Pandite
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

Toni K. Choueiri, David J. Figueroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, Robert J. Motzer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1071–1077.
https://doi.org/10.1158/1078-0432.CCR-14-1993
Published: 01 March 2015
View article titled, Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Open the PDF for Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial in another window
Includes: Supplementary data
Journal Articles

The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma

Toni K. Choueiri, André P. Fay, Robert Gagnon, Ying Lin, Brittany Bahamon, Victoria Brown, Jonathan E. Rosenberg, Thomas E. Hutson, Katherine L. Baker-Neblett, Christopher Carpenter, Yuan Liu, Lini Pandite, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (18): 5218–5226.
https://doi.org/10.1158/1078-0432.CCR-13-0491
Published: 16 September 2013
View article titled, The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Open the PDF for The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Howard A. Burris, III, Charles W. Taylor, Suzanne F. Jones, Kevin M. Koch, Melissa J. Versola, Niki Arya, Ronald A. Fleming, Deborah A. Smith, Lini Pandite, Neil Spector, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6702–6708.
https://doi.org/10.1158/1078-0432.CCR-09-0369
Published: 02 November 2009
View article titled, A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies in another window
Journal Articles

Phase I Trial of Pazopanib in Patients with Advanced Cancer

Herbert I. Hurwitz, Afshin Dowlati, Shermini Saini, Shawna Savage, A. Benjamin Suttle, Diana M. Gibson, Jeffrey P. Hodge, Elmar M. Merkle, Lini Pandite
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4220–4227.
https://doi.org/10.1158/1078-0432.CCR-08-2740
Published: 15 June 2009
View article titled, Phase I Trial of Pazopanib in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Pazopanib in Patients with Advanced Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Quincy S.C. Chu, Mary E. Cianfrocca, Lori J. Goldstein, Meg Gale, Nicholas Murray, Jill Loftiss, Nikita Arya, Kevin M. Koch, Lini Pandite, Ronald A. Fleming, Elaine Paul, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4484–4490.
https://doi.org/10.1158/1078-0432.CCR-07-4417
Published: 15 July 2008
View article titled, A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer in another window
Journal Articles

Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors

Wandena S. Siegel-Lakhai, Jos H. Beijnen, Walter L. Vervenne, Henk Boot, Marianne Keessen, Melissa Versola, Kevin M. Koch, Deborah A. Smith, Lini Pandite, Dirk J. Richel, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4495–4502.
https://doi.org/10.1158/1078-0432.CCR-07-0004
Published: 01 August 2007
View article titled, Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors
Open the PDF for Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors in another window
Journal Articles

A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

Paul R. Helft, Richard L. Schilsky, Frank J. Hoke, Daphne Williams, Hedy L. Kindler, Evie Sprague, Mark DeWitte, Helen K. Martino, John Erickson, Lini Pandite, Mark Russo, John M. Lambert, Maria Howard, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4363–4368.
https://doi.org/10.1158/1078-0432.CCR-04-0088
Published: 06 July 2004
View article titled, A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors in another window